Nov 11, 2008 - EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that it received approval from the U.S. FDA for double concentration Cardene I.V. (nicardipine hydrochloride) premixed injection.
The details can be read here.
No comments:
Post a Comment